Metastatic Nasopharyngeal Cancer Clinical Trial
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of nasopharyngeal cancer.
By enrolling patients with small metastases of nasopharyngeal cancer adapted to enrolled
criteria, this study will document for the first time the safety and the short and long term
efficacy of high-activity natural killer cells.
The safety will be evaluated by statistics of adverse reactions. The efficacy will be
evaluated according to local relief degree, progress free survival (PFS) and overall survival
(OS).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05198479 -
Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in
|
Phase 2 | |
| Recruiting |
NCT05385926 -
Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT03813394 -
Bevacizumab and Pembrolizumab Combination in EBER-ISH Positive NPC
|
Phase 1/Phase 2 |